Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

1. Editas Medicine and Bristol Myers Squibb (BMS) have extended their collaboration to develop engineered T cell therapies for cancer treatment. The partnership, initially established in 2016, focuses on using Editas' CRISPR gene-editing technology and BMS' expertise in drug development and commercialization.
2. The extended collaboration aims to advance multiple therapeutic candidates into clinical development, with the potential to address various types of cancer. The financial terms of the extended agreement have not been disclosed.
3. Separately, KalVista Pharmaceuticals is seeking a partner for its preclinical hereditary angioedema (HAE) program. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling, which can be life-threatening.
4. KalVista's HAE program is based on its proprietary plasma kallikrein inhibitors, which have shown promise in preclinical studies. The company hopes to find a partner to help advance the program into clinical development and eventually bring a new treatment option to patients with HAE.